Pulse Biosciences Files 8-K

TL;DR

Pulse Biosciences filed a routine 8-K, no major news.

AI Summary

Pulse Biosciences, Inc. filed an 8-K on June 4, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.

Why It Matters

This filing indicates Pulse Biosciences is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting purposes and does not disclose any new material risks or events.

Key Players & Entities

• Pulse Biosciences, Inc. (company) — Registrant
• June 4, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 001-37744 (file_number) — SEC File Number
• 46-5696597 (irs_number) — IRS Employer Identification No.
• 3957 Point Eden Way (address) — Principal Executive Offices
• Hayward (city) — Principal Executive Offices
• California (state) — Principal Executive Offices
• 94545 (zip_code) — Principal Executive Offices
• 510-906-4600 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock , par value $0.001 per share PLSE The Nasdaq Stock Mar

Filing Documents

• plse20240604_8k.htm (8-K) — 28KB
• ex_683312.htm (EX-99.1) — 16KB
• 0001437749-24-019182.txt ( ) — 178KB
• plse-20240604.xsd (EX-101.SCH) — 3KB
• plse-20240604_def.xml (EX-101.DEF) — 11KB
• plse-20240604_lab.xml (EX-101.LAB) — 15KB
• plse-20240604_pre.xml (EX-101.PRE) — 11KB
• plse20240604_8k_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On June 4, 2024, Pulse Biosciences, Inc. (the "Company") issued a press release announcing the commencement of its previously-announced rights offering pursuant to a registration statement filed on Form S-3 (File No. 333-278494), as modified by the post-effective amendment filed with the Securities and Exchange Commission ("SEC") on May 28, 2024, which was deemed effective by the SEC on May 31, 2024, including the prospectus contained therein, as further modified by the prospectus to be filed pursuant to Rule 424(b)(2) of the Securities Act of 1933, which contains the detailed terms of the rights offering and will be filed with the SEC on June 4, 2024. A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1. The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by Pulse Biosciences, Inc. dated June 4, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pulse Biosciences, Inc. By: /s/ Burke T. Barrett Burke T. Barrett President and Chief Executive Officer ( Principal Executive and Principal Financial Officer ) Date: June 4, 2024

View Full Filing

View this 8-K filing on SEC EDGAR